Skip to content
value.today
Rubius Therapeutics, Inc. logo

Rubius Therapeutics, Inc.

Formerly VL26, Inc.

Total raised
$216 M
2 rounds on record
Latest round
$101 M
Feb 2018
First round on record
Jun 2017
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Rubius Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2018$101 MNo. 2$50 to $250 million

Rubius Therapeutics, Inc.: Raise no. 2, Feb 2018

Investors in this round

27 investors had bought by the notice of Mar 1, 2018: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Rubius Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$101 M of $101 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew B. Oh · Executive Officer
  • Christopher L. Carpenter · Executive Officer
  • Joanne Protano · Executive Officer
  • Torben Straight Nissen · Executive Officer, Director
  • Catherine B. Sohn · Director
  • David Straight Epstein · Director
  • Francis B. Cuss · Director
  • Michael S. Rosenblatt · Director
  • Noubar B. Afeyan · Director
  • Robert S. Langer · Director
  • Roger S. Pomerantz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Amount sold shown in item 13 and number of investors shown in item 14 includes $20,199,963 from 6 non-US investors.”

Signed by Joanne Protano, Secretary. Source: SEC Form D, newest notice filed Mar 1, 2018. Read the notice at the SEC.

equitySEC
Jun 2017$115 MNo. 1$50 to $250 million

Rubius Therapeutics, Inc.: Raise no. 1, Jun 2017

Investors in this round

16 investors had bought by the notice of Jun 22, 2017: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Rubius Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$115 M of $120 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joanne Protano · Executive Officer
  • Torben Straight Nissen · Executive Officer, Director
  • David Straight Epstein · Director
  • Harvey F. Lodish · Director
  • Michael Barton Rosenblatt · Director
  • Noubar B. Afeyan · Director
  • Peter Barton Hutt · Director
  • Robert S. Langer · Director
  • Roger S. Pomerantz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Amount sold shown in item 13 and number of investors shown in item 14 includes $40,000,012 from 2 non-US investors.”

Signed by Joanne Protano, Secretary. Source: SEC Form D, newest notice filed Jun 22, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Rubius Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2018).

    SEC Form D · Mar 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2018

That is all the official record says: Rubius Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

In its own words

How the company describes itself to search engines on its website, word for word.

“Discover trusted Australia online casinos in 2025. Play pokies, live dealers, and games with fast payouts and rewarding bonuses.”

Source: The company's website · as of Nov 15, 2026

Products and services#

No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.

Investors#

7 named in official filings. Open an investor to see everything it has backed.

Investors in Rubius Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Flagship VentureLabs IV, LLCVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Flagship Ventures Fund IV General Partner LLCVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner, director (Form 3, 2018)SEC Form 3
Flagship Ventures Fund IV, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Flagship Ventures Fund IV-Rx, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Flagship Ventures Fund V, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Flagship Ventures Opportunities Fund I, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Flagship V VentureLabs Rx Fund, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 27 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Rubius Therapeutics, Inc.
NameRoleNamed in
Andrew B. OhExecutive officerMar 2018
Christopher L. CarpenterExecutive officerMar 2018
Joanne ProtanoExecutive officerMar 2018
Torben Straight NissenExecutive officerMar 2018
Catherine B. SohnDirectorMar 2018
David Straight EpsteinDirectorMar 2018
Francis B. CussDirectorMar 2018
Michael S. RosenblattDirectorMar 2018
Noubar B. AfeyanDirectorMar 2018
Robert S. LangerDirectorMar 2018
Roger S. PomerantzDirectorMar 2018
Torben Straight NissenDirectorMar 2018
Harvey F. LodishDirectorJun 2017
Michael Barton RosenblattDirectorJun 2017
Peter Barton HuttDirectorJun 2017

About

Company in Cambridge, United States.